# Sargramostim With Ipilimumab Containing Therapy in Patients With Solid Tumors

> **NCT05284214** · PHASE2 · WITHDRAWN · sponsor: **Partner Therapeutics, Inc.**

## Conditions studied

- Solid Tumor
- Solid Tumor, Adult

## Interventions

- **BIOLOGICAL:** Sargramostim
- **BIOLOGICAL:** Ipilimumab-containing therapy

## Key facts

- **NCT ID:** NCT05284214
- **Lead sponsor:** Partner Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-01
- **Primary completion:** 2025-09
- **Final completion:** 2025-09
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study did not commence.
- **Last updated:** 2023-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05284214

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05284214, "Sargramostim With Ipilimumab Containing Therapy in Patients With Solid Tumors". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05284214. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*